Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset-Reference-Cited by-同舟云学术

Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset

Published:2021-05-06 Issue: Volume: Page:096120332110142
ISSN:0961-2033
Container-title:Lupus
language:en
Short-container-title:Lupus

Author:

Elkhalifa Marwa¹²^ORCID,Orbai Ana-Maria²^ORCID,Magder Laurence S³,Petri Michelle²^ORCID,Alarcón Graciela S⁴^ORCID,Gordon Caroline⁵,Merrill Joan⁶,Fortin Paul R⁷,Bruce Ian N⁸,Isenberg David⁹^ORCID,Wallace Daniel¹⁰,Nived Ola¹¹^ORCID,Ramsey-Goldman Rosalind¹²,Bae Sang-Cheol¹³^ORCID,Hanly John G¹⁴,Sanchez-Guerrero Jorge¹⁵,Clarke Ann E¹⁶,Aranow Cynthia¹⁷,Manzi Susan¹⁸,Urowitz Murray¹⁵^ORCID,Gladman Dafna D¹⁵,Kalunian Ken¹⁹,Werth Victoria P²⁰,Zoma Asad²¹,Bernatsky Sasha²²,Khamashta Munther²³,Jacobsen SØren²⁴,Buyon Jill P²⁵,Dooley Mary Anne²⁶,Vollenhoven Ronald van²⁷²⁸²⁹,Ginzler Ellen³⁰,Stoll Thomas³¹,Peschken Christine³²,Jorizzo Joseph L³³,Callen Jeffery P³⁴,Lim Sam³⁵,Inanc Murat³⁶,Kamen Diane L³⁷,Rahman Anisur⁹,Steinsson Kristjan³⁸,Franks Andrew G³⁹

Affiliation:

1. Department of Medicine, Alexandria University, Alexandria, Egypt

2. Johns Hopkins University School of Medicine, Baltimore, MD, USA

3. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA

4. Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA

5. Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

6. Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

7. Division of Rheumatology, CHU de Québec – Université Laval, Quebec City, Canada

8. Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospital NHS Foundation Trust, Manchester Academic Health Science Center, Manchester, UK

9. Centre for Rheumatology Research, University College, London, UK

10. Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

11. Department of Clinical Sciences Lund, Lund University, Lund, Sweden

12. Northwestern University and Feinberg School of Medicine, Chicago, IL, USA

13. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea

14. Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada

15. Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada

16. Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

17. Feinstein Institute for Medical Research, Manhasset, NY, USA

18. Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, USA

19. UCSD School of Medicine, La Jolla, CA, USA

20. Division of Dermatology, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, Philadelphia, PA, USA

21. Lanarkshire Centre for Rheumatology, Hairmyres Hospital, Scotland, UK

22. Division of Rheumatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada

23. Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, King’s College London School of Medicine, London, UK

24. Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

25. Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY, USA

26. Division of Rheumatology and Immunology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA

27. Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, Netherlands

28. Free University (VU) Amsterdam, Amsterdam, Netherlands

29. Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

30. Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA

31. Department of Rheumatology, Kantonsspital, Schaffhausen, Switzerland

32. Department of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

33. Department of Dermatology, Weill Cornell Medicine, New York, NY, USA

34. Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA

35. Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, USA

36. Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

37. Division of Rheumatology, Medical University of South Carolina, Charleston, SC, USA

38. Department of Rheumatology, Center for Rheumatology Research Fossvogur Landspitali University Hospital, Reyjkavik, Iceland

39. Division of Rheumatology, Department of Medicine and The Department of Dermatology, New York University School of Medicine, New York, NY, USA

Abstract

Objective Anti-beta 2 glycoprotein I IgA is a common isotype of anti-beta 2 glycoprotein I in SLE. Anti-beta 2 glycoprotein I was not included in the American College of Rheumatology (ACR) SLE classification criteria, but was included in the Systemic Lupus International Collaborating Clinics (SLICC) criteria. We aimed to evaluate the prevalence of anti-beta 2-glycoprotein I IgA in SLE versus other rheumatic diseases. In addition, we examined the association between anti-beta 2 glycoprotein I IgA and disease manifestations in SLE. Methods The dataset consisted of 1384 patients, 657 with a consensus physician diagnosis of SLE and 727 controls with other rheumatic diseases. Anti-beta 2 glycoprotein I isotypes were measured by ELISA. Patients with a consensus diagnosis of SLE were compared to controls with respect to presence of anti-beta 2 glycoprotein I. Among patients with SLE, we assessed the association between anti-beta 2 glycoprotein I IgA and clinical manifestations. Results The prevalence of anti-beta 2 glycoprotein I IgA was 14% in SLE patients and 7% in rheumatic disease controls (odds ratio, OR 2.3, 95% CI: 1.6, 3.3). It was more common in SLE patients who were younger patients and of African descent (p = 0.019). Eleven percent of SLE patients had anti-beta 2 glycoprotein I IgA alone (no anti-beta 2 glycoprotein I IgG or IgM). There was a significant association between anti-beta 2 glycoprotein I IgA and anti-dsDNA (p = 0.001) and the other antiphospholipid antibodies (p = 0.0004). There was no significant correlation of anti-beta 2 glycoprotein I IgA with any of the other ACR or SLICC clinical criteria for SLE. Those with anti-beta 2 glycoprotein I IgA tended to have a history of thrombosis (12% vs 6%, p = 0.071), but the difference was not statistically significant. Conclusion We found the anti-beta 2 glycoprotein I IgA isotype to be more common in patients with SLE and in particular, with African descent. It could occur alone without other isotypes.

Funder

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Publisher

SAGE Publications

Subject

Rheumatology

Link

http://journals.sagepub.com/doi/pdf/10.1177/09612033211014248

Reference17 articles.

1. Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus

2. Isotype distribution and clinical relevance of anti-β2-glycoprotein I (β2-GPI) antibodies: importance of IgA isotype

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in diagnosis and treatment of pediatric antiphospholipid syndrome;Current Rheumatology Reports;2024-07-24

2. Association between Inflammation and Thrombotic Pathway Link with Pathogenesis of Depression and Anxiety in SLE Patients;Biomolecules;2023-03-20

3. Solid Phase Assays for Antiphospholipid Antibodies;Seminars in Thrombosis and Hemostasis;2022-06-08

4. Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome;Journal of Translational Autoimmunity;2021